Isatuximab, Dexamethasone, and Lenalidomide for Frail Multiple Myeloma Patients
Phase 2
40
about 2.1 years
18+
1 site in UT
About this study
This trial is testing a go-slow approach to treating multiple myeloma in very frail patients. The treatment starts with Isatuximab and dexamethasone, then gradually introduces lenalidomide. The goal is to see if this gentler start improves how well people stick to their treatment plan and improves their quality of life.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Isatuximab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
isatuximab
Secondary: Change in quality of life as per the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 domain, Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration, Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by relationship to study treatment, Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness, Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 5.0), Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, Overall survival (OS)
Oncology